Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 15, 2018

Primary Completion Date

December 15, 2018

Study Completion Date

December 15, 2018

Conditions
Cardiomyopathy Due to DrugHeart Failure, Systolic
Interventions
DRUG

Lisinopril

Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.

DRUG

Placebo Oral Tablet

Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.

Trial Locations (1)

48439

Genesys Regional Medical Center, Grand Blanc

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ascension Health

INDUSTRY

NCT03392740 - Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. | Biotech Hunter | Biotech Hunter